Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Geert Cauwenbergh is President and CEO of RXi Pharmaceuticas and also the Founder of Phase123, a company that is focused on bringing together investigators and sponsors for drug development and clinical studies. Dr. Cauwenbergh was the Founder and CEO of Barrier Therapeutics, acquired in 2008 by Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology. Dr. Cauwenbergh has held various executive positions with Johnson and Johnson, has authored over 100 publications and co-authored several books. Dr. Cauwenbergh received his Ph.D. in Medical Sciences from the Catholic University of Leuven, where he completed his Masters and undergraduate work.
Dermatology, Health care,